BioNxt Solutions Inc

BioNxt’s patented melt‑in‑mouth thin‑film platform offers a rapid, non‑invasive oral delivery for semaglutide, tackling 40 % of dysphagia patients and challenging injectable therapies.

BioNxt’s “Intention to Grant” from the EPO for a sublingual cladribine thin‑film could transform MS treatment and boost investor prospects.

BioNxt Solutions Inc. has made significant progress in its semaglutide oral dissolvable film program, completing proof-of-concept trials and reducing its debt by $225,010 through a settlement agreement.

BioNxt Solutions Inc. has received a formal notice from the European Patent Office to grant a patent for its innovative anticancer drug delivery technology, a key milestone for the company’s lead product BNT23001.